Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 in HIV-infected Patients: Efficacy and Tolerability of Grazoprevir 100mg/Elbasvir 50mg During 8 Weeks

Trial Profile

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 in HIV-infected Patients: Efficacy and Tolerability of Grazoprevir 100mg/Elbasvir 50mg During 8 Weeks

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms SAHIV
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.
    • 11 Jul 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2019.
    • 11 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top